Alexion to acquire Portola for $1.41B

Tuesday, 05. May 2020 13:54

Alexion Pharmaceuticals, Inc. announced on Tuesday it will acquire Portola Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company focused on life-threatening blood-related disorders. This deal values Portola at $1.41 billion.

Ludwig Hantson, Chief Executive Officer of Alexion said that this acquisition "represents an important next step in our strategy to diversify beyond C5. Andexxa is a strategic fit with our existing portfolio of transformative medicines and is well-aligned with our demonstrated expertise in hematology, neurology and critical care."

The companies agreed that Alexion would pay $18 per Portola share in cash, which represents a premium of 132% to Portola’s last closing price.

Related Links: Alexion Pharmaceuticals Inc.
Breaking the News / TF